Goldman Sachs Group Inc Esperion Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 916,011 shares of ESPR stock, worth $1.95 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
916,011
Previous 3,364,266
72.77%
Holding current value
$1.95 Million
Previous $9.02 Million
77.45%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ESPR
# of Institutions
198Shares Held
136MCall Options Held
2.72MPut Options Held
1.3M-
Wasatch Advisors Inc Salt Lake City, UT16.9MShares$35.9 Million0.2% of portfolio
-
Black Rock Inc. New York, NY14MShares$29.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$23 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$21.2 Million0.37% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.51MShares$13.9 Million0.01% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $142M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...